Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

08 Sep
Palliative Care Formulary September 2020 Update

This update contains 2 revised monographs.

The following monographs have undergone minor revision: Inhaled long-acting β2 agonists (LABAs); Strong opioids.

 
08 Sep
AHFS Drug Information logo
AHFS September 2020 Update

This update contains 4 new monographs, 24 revised monographs and 18 new MedWatch alerts.

New monographs: Selpercatinib; Inebilizumab-Cdon; Lurbinectedin; Decitabine And Cedazuridine

Revised monographs: Remifentanil; Tapentadol; Dolutegravir and Rilpivirine; Dolutegravir and Lamivudine; Brolucizumab; HYDROcodone; Levorphanol; Codeine; Meperidine; OxyMORphone; OxyCODONE; Morphine; Methadone; Bacitracin; Opium; Pentazocine; FentaNYL; Butorphanol; Nalbuphine; Neomycin; Opiate Agonists General Statement; SUFentanil; Buprenorphine; TraMADol

New MedWatch alerts on the following monographs: Remifentanil; Tapentadol; HYDROcodone; Levorphanol; Codeine; Meperidine; oxyMORphone; OxyCODONE; Morphine; Methadone; Opium; Pentazocine; FentaNYL; Butorphanol; Nalbuphine; SUFentanil; Buprenorphine; TraMADol

 
08 Sep
Martindale logo
Martindale: The Complete Drug Reference September 2020 Update

This update contains 5 new monographs. Preparations have been updated for 7 countries.

New monographs:

• Cefiderocol is a siderophore cephalosporin approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

• Givosiran, a small interfering RNA, that is used in the treatment of acute hepatic porphyria.

• Lasmiditan is a selective serotonin agonist and can be used to treat acute migraine.

• Luspatercept is a recombinant fusion protein that acts as an erythroid maturation agent. It is used to treat transfusion-dependent anaemia associated with beta-thalassaemia or myelodysplastic syndromes.

• Voxelotor is a haemoglobin oxygen-affinity modulator in the management of sickle-cell disease.

Proprietary Preparations and Manufacturers updated for the following countries and regions:

• Hungary
• Indonesia
• New Zealand
• Russia
• Turkey
• USA†
• UK†
† Countries updated on an ongoing basis

 
08 Sep
British National Formulary for Children logo
BNF for Children September 2020 Update

This update contains 6 significant changes, 1 dose change and 2 new monographs.

Significant Changes:
• Amphotericin: name change to amphotericin B.
• Amphotericin B: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Cytarabine: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Daunorubicin: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Doxorubicin hydrochloride: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Flucytosine: Updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency [MHRA/CHM advice].

Dose Change:
• Cefixime [update to dosing for uncomplicated gonorrhoea].

New Monographs:
• Cefazolin.
• Veklury® [remdesivir].

For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

 
08 Sep
British National Formulary logo
British National Formulary September 2020 Update

This update contains 29 significant changes, 5 dose changes and 4 new monographs.

Significant Changes:
• Aflibercept: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Amphotericin: name change to amphotericin B.
• Amphotericin B: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Andexanet alfa (Ondexxya®): Commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa [MHRA/CHM advice].
• Atezolizumab (Tecentriq®) with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [NICE guidance].
• Atezolizumab (Tecentriq®) with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer [NICE guidance].
• Axitinib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Bevacizumab: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• BNF updates for Community Practitioner Nurse Prescribers: For BNF app and online versions of the BNF – list of medicinal preparations (renamed as Approved list for prescribing by Community Practitioner Nurse Prescribers (NPF)) updated with indications for use by Community Practitioner Nurse Prescribers and links to BNF monographs; general guidance and treatment summaries for use by Community Practitioner Nurse Prescribers have also been added. For BNF print editions – list of medicinal preparations (Nurse Prescribers’ Formulary (NPF)) updated with indications for use by Community Practitioner Nurse Prescribers and cross-references to BNF monographs. For further information, see How to use the NPF above the list of medicinal preparations.
• Cabozantinib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Capecitabine: Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe and fatal toxicity [MHRA/CHM advice].
• Cytarabine: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Daunorubicin: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Daunorubicin with cytarabine: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Doxorubicin hydrochloride: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Flucytosine: Updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency [MHRA/CHM advice].
• Fluorouracil: Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe and fatal toxicity [MHRA/CHM advice].
• Irinotecan hydrochloride: Liposomal and lipid-complex formulations: name change to reduce medication errors [MHRA/CHM advice].
• Lenvatinib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Nintedanib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Pazopanib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Ponatinib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Ramucirumab: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Regorafenib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Sorafenib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Sunitinib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Tegafur with gimeracil and oteracil: Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe and fatal toxicity [MHRA/CHM advice].
• Tivozanib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].
• Vandetanib: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection [MHRA/CHM advice].

Dose Changes:
• Cefixime [update to dosing for uncomplicated gonorrhoea].
• Ofloxacin [update to dosing for complicated skin and soft-tissue infections].
• Ofloxacin [update to dosing for complicated urinary-tract infections].
• Ofloxacin [update to dosing for lower respiratory-tract infections].
• Ofloxacin [update to dosing for urinary-tract infections].

New Monographs:
• Cefazolin.
• Quofenix® [delafloxacin].
• Sarclisa® [isatuximab].
• Veklury® [remdesivir].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

 
08 Sep
Stockley's Interactions Checker_logo
Stockley’s Interactions Checker September 2020 Update

New and updated interactions now available

For September, 609 new interactions have been added, and 6 existing interactions have been updated.

 
View more